Dublin - May 8, 2019 - Cosmo Pharmaceuticals NV (SIX: COPN) announced today that it has entered into a new exclusive supply and distribution agreement for Eleview with Medtronic for the US, China and South America, having in the meantime terminated by mutual consent the co-marketing agreement with Olympus.
Further, Cosmo announced that it has entered into a Collaboration Agreement with Medtronic to start a research collaboration in Artificial Intelligence in GI and explore various technological solutions and related business opportunities.
"Thanks to the highly recognized expertise in GI and a decade of hard work and investments in endoscopy, we are now able to consistently strengthen our cooperation with Medtronic, the biggest player in medical technology. The Eleview deal allows the franchise to expand with an unrivalled marketing firepower, while the collaboration deal opens up new exciting perspectives for Artificial Intelligence in GI and marks Cosmo as a significant player in one of the most cutting-edge fields. We are proud of these new opportunities" said Alessandro Della Chà, CEO of Cosmo.